Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

13.3%

2 terminated/withdrawn out of 15 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

20%

3 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

6(46.2%)

Phase 2

4(30.8%)

Phase 3

3(23.1%)

13Total

Phase 1(6)

Phase 2(4)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT00807027Phase 3Completed

Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea

Role: lead

NCT06620510Completed

Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea

Role: lead

NCT06699771Phase 1Recruiting

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Role: lead

NCT06341647Phase 1Withdrawn

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Role: lead

NCT00965718Phase 2Completed

Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer

Role: lead

NCT00699816Phase 3Completed

Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients

Role: lead

NCT01890291Completed

Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.

Role: lead

NCT01897610Phase 2Completed

Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC

Role: lead

NCT03983967Phase 1Completed

Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation

Role: lead

NCT02856815Phase 2Completed

Safety and Efficacy of "Immuncell-LC" in TACE Therapy

Role: lead

NCT05238532Phase 1Withdrawn

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS

Role: lead

NCT05258331Phase 1Unknown

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

Role: lead

NCT04969731Phase 3Recruiting

Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Role: lead

NCT03778619Phase 1Unknown

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Role: lead

NCT02854839Phase 2Completed

A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma

Role: lead

All 15 trials loaded